mScarlet/LUC Reporter Cell Line - EMT6

The EMT6 cell line is a highly characterized murine model of mammary carcinoma, originally derived from an implanted hyperplastic alveolar nodule in a BALB/c mouse. It serves as a cornerstone in breast oncology research, particularly valued as a robust syngeneic model that faithfully replicates the complex tumor microenvironment, distinct responses to hypoxia, and the aggressive localized growth characteristic of breast malignancies. The mScarlet/Luc Reporter Cell Line - EMT6 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both the exceptionally bright, monomeric red fluorescent protein mScarlet and firefly luciferase (Luc). This advanced dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental epithelial morphology, the intrinsic biological properties, or the highly tumorigenic capacity of the original parental EMT6 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the EMT6 model for comprehensive translational breast cancer research. For in vitro studies, the intense red fluorescence provided by mScarlet expression allows researchers to easily visualize cellular dynamics, accurately quantify proliferation rates, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and distant metastasis through bioluminescence imaging (BLI). Because it is a murine-derived cell line, the EMT6-mScarlet/Luc model is engrafted into immunocompetent, syngeneic BALB/c mice to establish clinically relevant orthotopic mammary fat pad models or reliable subcutaneous allografts. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, radiation therapies, and—crucially—emerging immunotherapies (such as immune checkpoint inhibitors or adoptive cell transfers), facilitating the real-time, accurate quantification of localized tumor burden and disseminated disease in living subjects with fully intact immune systems.